The EPO granted Patent EP3870230A1 to Finice S.r.l. for conjugates of bile acids and their derivatives intended for active molecule delivery. The patent, published March 25, 2026, includes nine named inventors and covers pharmaceutical compositions using bile acid conjugates as delivery vehicles. Coverage extends across 31 designated contracting states under the European Patent Convention.

Pharmaceutical companies developing drug delivery systems utilizing bile acid technology should conduct freedom-to-operate analyses to assess potential infringement risks. Drug manufacturers and researchers working with bile acid-based delivery mechanisms should review the patent claims to understand protected compositions and methods before advancing related product development programs.